WO2001051644A3 - ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN - Google Patents
ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN Download PDFInfo
- Publication number
- WO2001051644A3 WO2001051644A3 PCT/DE2001/000130 DE0100130W WO0151644A3 WO 2001051644 A3 WO2001051644 A3 WO 2001051644A3 DE 0100130 W DE0100130 W DE 0100130W WO 0151644 A3 WO0151644 A3 WO 0151644A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- domain
- human
- antibody
- domains
- dna sequences
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01911351A EP1250443A2 (de) | 2000-01-14 | 2001-01-10 | ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN C $g(m)?3- und C $g(m)?4- DOMÄNEN |
US10/181,305 US20040175786A1 (en) | 2000-01-14 | 2001-01-10 | Anti-cd3 single-chain antibodies having human cmu3 and cmu4 domains |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10001372A DE10001372A1 (de) | 2000-01-14 | 2000-01-14 | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
DE10001372.4 | 2000-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001051644A2 WO2001051644A2 (de) | 2001-07-19 |
WO2001051644A3 true WO2001051644A3 (de) | 2001-12-06 |
Family
ID=7627538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2001/000130 WO2001051644A2 (de) | 2000-01-14 | 2001-01-10 | ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040175786A1 (de) |
EP (1) | EP1250443A2 (de) |
DE (1) | DE10001372A1 (de) |
WO (1) | WO2001051644A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861078B1 (fr) * | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
JP6205363B2 (ja) * | 2011-09-26 | 2017-09-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | ハイブリッド定常領域 |
KR20160130463A (ko) | 2014-03-05 | 2016-11-11 | 유씨비 바이오파마 에스피알엘 | 다량체 Fc 단백질 |
GB201511787D0 (en) * | 2015-07-06 | 2015-08-19 | Ucb Biopharma Sprl | Proteins |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
WO2019156566A1 (en) | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
WO2022258606A1 (en) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
WO2023227594A1 (en) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof |
WO2023237541A1 (en) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
WO2024013401A1 (en) | 2022-07-15 | 2024-01-18 | Gadeta B.V. | Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
WO2024100136A1 (en) | 2022-11-08 | 2024-05-16 | Gadeta B.V. | Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
-
2000
- 2000-01-14 DE DE10001372A patent/DE10001372A1/de not_active Withdrawn
-
2001
- 2001-01-10 US US10/181,305 patent/US20040175786A1/en not_active Abandoned
- 2001-01-10 WO PCT/DE2001/000130 patent/WO2001051644A2/de not_active Application Discontinuation
- 2001-01-10 EP EP01911351A patent/EP1250443A2/de not_active Withdrawn
Non-Patent Citations (9)
Title |
---|
A. PLÜCKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragments.", IMMUNOTECHNOLOGY, vol. 3, no. 2, June 1997 (1997-06-01), Amsterdam, die Niederlande, pages 83 - 105, XP004126672 * |
H. CHEN: "Single-chain antibody (scFVOKT3)-induced T leukemia cell apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), VSA, pages 31, XP002170003 * |
I. CHOI ET AL.: "Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 1, January 2001 (2001-01-01), Weinheim, Deutschland, pages 94 - 106, XP001002634 * |
L. NORDERHAUG ET AL.: "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 204, no. 1, 12 May 1997 (1997-05-12), Amsterdam, die Niederlande, pages 77 - 87, XP004061470 * |
R. SMITH ET AL.: "Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.", THE JOURNAL OF IMMUNOLOGY, vol. 154, no. 5, 1 March 1995 (1995-03-01), Baltimore; MD, VSA, pages 2226 - 2236, XP002170004 * |
S. HU ET AL.: "Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.", CANCER RESEARCH, vol. 56, no. 13, 1 July 1996 (1996-07-01), Baltimore, MD, VSA, pages 3055 - 3061, XP000645454 * |
S. MA ET AL.: "Expression and characterization of a divalent chimeric anti-human CD3 single-chain antibody.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 43, no. 2, February 1996 (1996-02-01), Oxford, Grossbritannien, pages 134 - 139, XP002083387 * |
T. OLAFSEN ET AL.: "IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.", IMMUNOTECHNOLOGY, vol. 4, no. 2, October 1998 (1998-10-01), Amsterdam, die Niederlande, pages 141 - 153, XP004153638 * |
V. SÖRENSEN ET AL.: "Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG.", THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 8, 15 April 1996 (1996-04-15), Baltimore, MD, VSA, pages 2858 - 2865, XP002170005 * |
Also Published As
Publication number | Publication date |
---|---|
DE10001372A1 (de) | 2001-08-02 |
EP1250443A2 (de) | 2002-10-23 |
WO2001051644A2 (de) | 2001-07-19 |
US20040175786A1 (en) | 2004-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001051644A3 (de) | ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN | |
MX9504802A (es) | Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. | |
WO2002016401A3 (en) | Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof | |
WO1994029451A3 (en) | Humanised antibodies | |
WO2003034903A3 (en) | Psma antibodies and protein multimers | |
IL162117A0 (en) | Humanized collagen antibodies and methods utilizing the same | |
AU3117201A (en) | Methods and compositions for generating human monoclonal antibodies | |
PT2305715T (pt) | Anticorpo monoclonal para a proteína de ligação a osteoprotegerina | |
WO2003072736A3 (en) | Reagents and treatment methods for autoimmune diseases | |
UA106036C2 (uk) | Анти-мезотелінове антитіло та його застосування | |
WO2003078468A3 (de) | Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung | |
GEP20074222B (en) | Antibodies to cd40 | |
WO2002002773A3 (en) | Dual specificity antibodies and methods of making and using | |
DE60235079D1 (de) | Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper | |
CA2068222A1 (en) | Monoclonal antibodies | |
WO2002032375A3 (en) | Uses of monoclonal antibody 8h9 | |
WO2002015846A3 (en) | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders | |
WO2003048194A3 (de) | Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie | |
WO2003010201A3 (en) | Blood group antigen fusion polypeptides and methods of use thereof | |
DE69535562D1 (de) | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden | |
WO2000074729A3 (en) | Alpha or beta emitters to fragments in radioimmunotherapy | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
WO2002094194A3 (en) | Compositions and methods for inhibiting metastasis | |
DE50104015D1 (de) | Verfahren zur selektiven bestimmung von blockierenden autoantikörpern gegen den tsh-rezeptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001911351 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001911351 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10181305 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001911351 Country of ref document: EP |